Industry Groups Seek More Options In Responding To DSCSA Verification Requests
Executive Summary
PhRMA and AAM suggest the US FDA should give pharmaceutical manufacturers more time to respond to requests from trading partners to verify that suspect and illegitimate products had been received. They point out that while DSCSA requires responses to verification requests be made within 24 hours, the law allows FDA to make exceptions.
You may also be interested in...
FDA Warning Letter Hits Distributor McKesson For Allowing Diversion Of Opioids And Other Medications
FDA has issued its first warning letter under DSCSA to San Francisco-based distributor McKesson Corp. for failing to exercise adequate control over products that were tampered with while stored in its facility. The firm was also chastised for its lax response to reports from pharmacies that opioids and other prescription drugs were removed from bottles and replaced with other drugs while the bottles were in its possession.
FDA Outlines Systems Manufacturers Should Have In Place For Handling Suspect Drugs Under DSCSA
Manufacturers need to have robust verification processes in place and actively communicate with their trading partners to handle suspect drugs that are not properly serialized under DSCA, FDA draft guidance document says.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”